TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

entitled “Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments”. Commercially known as “ACTA Technology” (Automated Cancer Treatment ...

entitled “Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments”. Commercially known as “ACTA Technology” (Automated Cancer Treatment Assessment), ...

A pioneering new treatment promises to tackle a wider range of cancers, with fewer side-effects than conventional radiotherapy. It also takes less than a second. In a series of vast underground ...

[16] These results suggest that ejaculatory disorder caused by silodosin associated with very large improvements in patients with benign prostatic hyperplasia. On the other hand, 76% of the ...

its experimental therapy for congenital adrenal hyperplasia (CAH). CAH, a group of genetic disorders affecting adrenal glands, is characterized by excessive levels of androstenedione (A4), a ...